Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 20/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 8/20 | 0.54 |
| ▸ | FLT3 | P36888 | 2/20 | 0.54 |
| ▸ | KIT | P10721 | 8/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.50 |
| ▸ | MET | P08581 | 3/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31474156 | 0.83 | CSF1R (0.56) | CSF1RPDGFRAFLT3KITPDGFRB | |
| SCHEMBL28341053 | 0.80 | CSF1R (0.61) | CSF1RPDGFRAFLT3KITPDGFRB | |
| SCHEMBL2416158 | 0.79 | CSF1R (0.54) | CSF1RPDGFRAFLT3KITPDGFRB | |
| SCHEMBL16060927 | 0.79 | CSF1R (0.56) | CSF1RPDGFRAFLT3KITPDGFRB | |
| SCHEMBL30086949 | 0.79 | CSF1R (0.54) | CSF1RPDGFRAFLT3KITPDGFRB | |
| SCHEMBL28341041 | 0.78 | CSF1R (0.51) | CSF1RPDGFRAFLT3KITPDGFRB | |
| SCHEMBL23900628 | 0.77 | CSF1R (0.62) | CSF1RPDGFRAFLT3KITPDGFRB | |
| SCHEMBL16028387 | 0.77 | CSF1R (0.57) | CSF1RPDGFRAFLT3KITPDGFRB | |
| SCHEMBL30086819 | 0.77 | CSF1R (0.57) | CSF1RPDGFRAFLT3KITPDGFRB | |
| SCHEMBL574068 | 0.77 | KDR (0.52) | CSF1RPDGFRAFLT3KITPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11591328-B2 | Highly active CSF1R inhibitor compound | XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20200399265-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | ADLAI NORTYE BIOPHARMA CO., LTD. (CN) | 2020-12-24 | — | — | US | disclosed |
| EP-3744718-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | Adlai Nortye Biopharma Co., Ltd. (CN) | 2020-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11591328-B2 | Highly active CSF1R inhibitor compound | CSF1R, CSF3R, CD209 | CSF1R 1/4885PDGFRA 94/4885FLT3 4/4885 |
| US-20200399265-A1 | HIGHLY ACTIVE CSF1R INHIBITOR COMPOUND | CSF1R, CSF3R, CD209 | CSF1R 1/4885PDGFRA 94/4885FLT3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.